|
|
Post by falconquest on Jun 24, 2015 19:08:57 GMT -5
I don't understand the entire process of attaching the insulin particle to the Technosphere particle other than the fact that it is a mist/drying process. So here is the question. Let's say SNY buys Afrezza from Mannkind. What do they get exactly? Do they obtain that process for combining insulin to Technosphere? How does that protect Mannkind from SNY attaching other particles? Al said previously that SNY has access to the "new process". What does that mean? Is Technosphere really something that can be "separated" from whatever is attached to it? Would SNY still have to buy the Technosphere particle from Mannkind if they bought the rights to Afrezza? Does each end product stand on it's own as a separate product? (I think I know the answer there) Someone help me out here. Obviously licensure plays a role. My point here is, can Afrezza be sold off separate from Mannkind as some suggest? Thanks!
|
|
|
|
Post by peppy on Jun 24, 2015 19:15:50 GMT -5
|
|
|
|
Post by peppy on Jun 24, 2015 19:19:15 GMT -5
electrostatically charged to bind.
separately, interesting the video mentioned the PH of the alveoli being neutral , and that helping the absorption. added, ph neutral means no charge. 7
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 24, 2015 19:19:58 GMT -5
If they bought just afrezza, they would gain the knowhow (and the equipment) necessary to create the product(s). They would be granted to use FDKP + Insulin to create Afrezza. Im sure they would be contractually obligated to this. Because of the patent protection around the devices, and around FDKP and isomers, they would be limited to just insulin.
|
|
|
|
Post by falconquest on Jun 24, 2015 19:24:27 GMT -5
Ok, but would there then be an ongoing payment to Mannkind for the "rights" to Technosphere? I guess that is really the heart of my question.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 24, 2015 19:27:05 GMT -5
Ok, but would there then be an ongoing payment to Mannkind for the "rights" to Technosphere? I guess that is really the heart of my question. Depends on the deal. If they bought it lock stock and barrel, maybe not? If they only bought the rights, Im sure MNKD would maintain some licensing. |
|
|
|
Post by peppy on Jun 24, 2015 19:29:37 GMT -5
interesting the video talked about proteins, peptides. They usually carry a negative charge.
Anyway, the proteins and technosphere particles are bond by charge.
Salt the sodium and the chloride are bond by charge. You have to love the atom.
Na+Cl-
|
|
|
|
Post by falconquest on Jun 24, 2015 19:31:40 GMT -5
...and if that were the case, what would preclude Sanofi from attaching any other particle to Technosphere. In other words.....who "owns" the technology and are they really separable? Would Mannkind simply license other companies in the future to produce products on their own while paying Mannkind for the rights to Technosphere? Think about how huge that could be. They do nothing (cogs is minutia) and collect licensing fees right and left.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 24, 2015 19:32:24 GMT -5
...and if that were the case, what would preclude Sanofi from attaching any other particle to Technosphere. In other words.....who "owns" the technology and are they really separable? Would Mannkind simply license other companies in the future to produce products on their own while paying Mannkind for the rights to Technosphere? Think about how huge that could be. They do nothing (cogs is minutia) and collect licensing fees right and left. In your example, MNKD would own technosphere. |
|
|
|
Post by falconquest on Jun 24, 2015 19:33:29 GMT -5
So there would be an ongoing fee paid to Mannkind?
|
|
|
|
Post by falconquest on Jun 24, 2015 19:42:36 GMT -5
Sorry fugacity,
So if what you say is true then Sanofi in effect cannot purchase just Afrezza, they would haven to purchase all of Mannkind. .....which is why a buy-out by Sanofi may never happen.
|
|
|
|
Post by mannmade on Jun 24, 2015 20:06:45 GMT -5
...and if that were the case, what would preclude Sanofi from attaching any other particle to Technosphere. In other words.....who "owns" the technology and are they really separable? Would Mannkind simply license other companies in the future to produce products on their own while paying Mannkind for the rights to Technosphere? Think about how huge that could be. They do nothing (cogs is minutia) and collect licensing fees right and left. If licensed then Mnkd owns TS. And if so, Sanofi being a Global company of large size would not risk patent infringement by making drugs with TS outside their deal with Mnkd. Furthermore Mnkd is likely to set up process and guidelines for (with) Sny which ensure compliance with terms of a licensing agreement so that Sny takes all reasonable measures to protect the technology to allieviate having to chase down patent infringement cases by others. Regarding licensing to others Mnkd has stated as recently as today's Jmp call that they do not see as much revenue is licensing TS to other companies to attach their own drugs/API so they are currently working internally on products they can own completely and perhaps do other distribution deals on. |
|
|
|
Post by dallasfan on Jun 24, 2015 21:23:05 GMT -5
I would guess there would be a licensing deal for the TS process also.
|
|
|
|
Post by peppy on Jun 24, 2015 22:41:25 GMT -5
Attachment Deleted
Attachment Deleted Carrier Particles Clinical pharmacology studies showed that carrier particles [see Description (11)] are not metabolized and are eliminated unchanged in the urine following the lung absorption. Following oral inhalation of AFREZZA, a mean of 39% of the inhaled dose of carrier particles was distributed to the lungs and a mean of 7% of the dose was swallowed. The swallowed fraction was not absorbed from the GI tract and was eliminated unchanged in the feces
Attachment Deleted |
|
|
|
Post by mnholdem on Jun 26, 2015 9:07:04 GMT -5
Sanofi has already secured the rights to manufacture, as part of the Agreement, not only Afrezza but very likely the GLP-1 that is mentioned in the Agreement, a drug that Sanofi apparently wanted to protect.
Sanofi can buy the rights to Afrezza, while MannKind continues to own proprietary rights to Technosphere. Ongoing Technosphere licensing fees will almost certainly be part of any acquisition of Afrezza rights, some of the patents and possibly even the Danbury manufacturing facilities.
However, all future Technosphere drug deals involving acquisition will include royalties on sales and licensing fees on the manufacturing process.
|
|
